Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled Safety, Pharmacokinetics and Efficacy Study of CA-008 in Subjects Undergoing Bunionectomy

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Safety, Pharmacokinetics and Efficacy Study of CA-008 in Subjects Undergoing Bunionectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2018

At a glance

  • Drugs CA-008 (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Concentric Analgesics
  • Most Recent Events

    • 08 Nov 2018 According to a Concentric Analgesics media release, the company expects to present complete data (including pharmacokinetics and full 28-day follow-up results) from this trial at upcoming scientific meetings in 2019.
    • 08 Nov 2018 Primary endpoint (Change in Post-surgical pain based on the weighted sum of pain intensity (SPI) assessments over 96 hours of the NRS scores = Area Under the Curve (AUC): highest dose of CA-008 (4.2 mg) versus placebo) has been met, according to a Concentric Analgesics media release.
    • 08 Nov 2018 Topline results of this trial presented in a Concentric Analgesics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top